<DOC>
	<DOCNO>NCT02967510</DOCNO>
	<brief_summary>A Phase 2 , Dose-ranging , 12-week Randomized , Double-blind , Placebo control , Parallel-group Study Evaluating Efficacy Safety Three Formulations Ultra-low Dose Estriol Vaginal Gel ( 0.005 % Estriol Vaginal Gel , 0.002 % Estriol Vaginal Gel , 0.0008 % Estriol Vaginal Gel ) Treatment Vaginal Dryness Postmenopausal Women Vulvovaginal Atrophy . Vulvovaginal atrophy natural consequence progressive estrogen deficiency occur menopause . Epidemiological data indicate 50 % otherwise healthy woman 60 year age experience symptom related urogenital atrophy vaginal dryness , dyspareunia , burning , itching , well urinary complaint infection low urinary tract . As alteration frequently affect quality life postmenopausal woman , important doctor detect presence offer treatment option . Estrogen therapy effective treatment moderate severe symptom vulvar vaginal atrophy . One advantage local treatment estrogen avoidance first-pass liver metabolism , make possible use lower dos estrogen compare oral therapy ; local route also minimize systemic adverse effect . The search therapeutic alternative may present improvement relation current product encourage .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety Three Formulations Ultra-low Dose Estriol Vaginal Gel ( 0.005 % , 0.002 % , 0.0008 % Estriol Vaginal Gel ) Treatment Vaginal Dryness Postmenopausal Women With Vulvovaginal Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<criteria>1 . Capable understanding write informed consent , provide sign witness write informed consent , agree comply protocol procedure assessments 2 . Age &gt; 40 &lt; 80 year 3 . Postmenopausal ( ≥12 month since last spontaneous menstrual period , 6 month spontaneous amenorrhea serum FSH level &gt; 40 IU/L , ≥6 week since bilateral oophorectomy without hysterectomy ) 4 . BMI ≤36 kg/m2 5 . Vaginal Maturation Index ≤ 5 % superficial cell vaginal smear 6 . Vaginal pH &gt; 5 7 . Moderate severe vaginal dryness currently report bothersome symptom vaginal atrophy . 8 . Documented negative mammogram within 9 month prior randomization , normal breast examination screen . 9 . Negative Papanicolau test screening ( woman cervix ) . 1 . Subjects contraindication hormone therapy estrogen diagnose history : malignant premalignant lesion breast and/or endometrium , malignancy colon , malignant melanoma , hepatic tumor , venous thromboembolic condition ( include deep vein thrombosis pulmonary embolism ) , arterial thromboembolic condition ( include angina pectoris , myocardial infarction , cerebrovascular accident ) , coagulopathies , vaginal bleed unknown etiology , acute liver disease history liver disease long liver function test fail return normal , porphyria . 2 . Subjects abnormal laboratory value screen investigator considers clinically relevant purpose study . 3 . Subjects medicalsurgical pathology control time inclusion study 4 . Subjects acute chronic condition whose management progression may interfere subject´s participation study . 5 . Subject uncontrolled hypertension ( &gt; 140 mmHg systolic blood pressure and/or ≥90 mmHg diastolic blood pressure ) . 6 . Subjects Grade II high uterovaginal prolapse . 7 . Subjects uterine polyp . 8 . Subjects symptomatic and/or large uterine fibroid ( &gt; 3 cm ) and/or palpable fibroid gynecological examination . 9 . Subjects urogenital surgery within 3 month baseline visit . 10 . Subjects sign symptom suggestive infection genital urinary tract require treatment start study . 11 . In woman uterus , evidence hyperplasia , cancer endometrial pathology endometrial biopsy . 12 . Subjects receive follow treatment within specified time period prior screen procedure : type nonhormonal vulvovaginal treatment 7 day ( include cosmetic expect impact vaginal pH special feminine wash gel ) ; phytoestrogens route within 1 month ; vaginal hormone therapy within 1 month ; hormone therapy ( estrogen alone , progestin alone estrogen/progestin combination ) oral , intrauterine transdermal route within 2 month ; progestational implant , estrogen , estrogen/progestational injectable within 3 month ; estrogen pellet therapy progestin injectable drug therapy within 6 month ; percutaneous estrogen lotion gel within 1 month ; testosterone testosterone derivative , DHEA , tibolone , SERMs route within 2 month ; 13 . Subjects receive antiepileptic drug ( barbiturate , hydantoin , carbamazepine ) , certain antibiotic antiinfective medicinal product ; phenylbutazone ; preparation base medicinal plant contain St. John 's Wort . 14 . Subjects allergic component medication study . 15 . Subjects currently participate participate experimental evaluation product within 8 week start study</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>